Publications 2016 2019

Filter
Meeting Abstract
2018

Combined Targeting of BET Family Proteins and BCL2 Is Synergistic in Acute Myeloid Leukemia Cells Overexpressing S100A8 and S100A9

Karjalainen, R., Liu, M., Kumar, A., Parsons, A., He, L., Malani, D. R., Kontro, M., Porkka, K. & Heckman, C. A., 2018, In : Blood. 132

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Open Access

Genome-Scale CRISPR Screens Identify Essential Genes for Sensitivity to Natural Killer Cells in Hematological Malignancies

Dufva, O., Klievink, J., Saeed, K., Kankainen, M., Ilander, M., Hannunen, T., Lagstrom, S., Ellonen, P., Lee, D. A. & Mustjoki, S., 29 Nov 2018, In : Blood. 132, 2 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Majumder, MM., Leppä, A-M., Hellesøy, M., Dowling, P., Malyutina, A., Bazou, D., Andersson, E. I., Parsons, A., Tang, J., Kallioniemi, O-P., Mustjoki, S. M., O'Gorman, P., Wennerberg, J. K., Porkka, K. V. K., Gjertsen, B-T. & Heckman, C. A., 2018, In : Blood. 132

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Open Access

Somatic Mutations in CD8+T Cells in Patients with Chronic Immune Thrombocytopenia Are Associated with Increased Clonality and Cytotoxic Phenotype of CD8+T Cells

Rajala, H., Savola, P., Lundgren, S., Eldfors, S., Kelkka, T., Ebeling, F. & Mustjoki, S., 29 Nov 2018, In : Blood. 132, 3 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

2017

Characterization of Immunological Profiles with Clinical Significance in Patients with Classical Hodgkin Lymphoma

Karihtala, K., Leivonen, S-K., Karjalainen-Lindsberg, M-L. & Leppa, S., 7 Dec 2017, In : Blood. 130, 1 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

CHRONIC MYELOID LEUKEMIA PATIENTS WERE NOT DIFFERENT IN MOLECULAR RELAPSE AFTER STOPPING IMATINIB IN MR4 WHETHER RESIDUAL DISEASE WAS DETECTED OR NOT - WHEN ADJUSTING FOR NUMBER OF CONTROL TRANSCRIPTS

Pfirrmann, M., Mahon, F-X., Guilhot, J., Richter, J., Almeida, A., Janssen, J. J., Mayer, J., Koskenvesa, P., Panayiotidis, P., Olsson-Stromberg, U., Berger, M. G., Diamond, J., Ehrencrona, H., Kairisto, V., Polakova, K. M., Mueller, M. C., Mustjoki, S., Hochhaus, A., Saussele, S. & Hjorth-Hansen, H., 26 Jun 2017, In : Haematologica. 102, p. 153-153 1 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

CLINICAL AND IMMUNOLOGICAL EFFECTS OF NILOTINIB IN COMBINATION WITH PEGYLATED INTERFERON-A2B IN PATIENTS WITH SUBOPTIMAL MOLECULAR RESPONSE ON IMATINIB (NORDDUTCHCML009)

Geelen, I., Olsson-Stromberg, U., Mustjoki, S., Richter, J., Blijlevens, N., Smit, W., Gjertsen, B., Gedde-Dahl, T., Markevarn, B., Koppes, M., Westerweel, P., Janssen, J. & Hjorth-Hansen, H., 26 Jun 2017, In : Haematologica. 102, p. 435-435 1 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Copanlisib (COP) in patients with relapsed or refractory indolent B-cell lymphoma: primary results of the pivotal Chronos-1 study

Dreyling, M., Santoro, A., Mollica, L., Leppa, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., Ozcan, M., Kosinova, M., Bouabdallah, K., Morschhauser, F., Stevens, D. A., Trevarthen, D., Giurescu, M., Kupit, L., Childs, B. H. & Zinzani, P. L., Sep 2017, In : Oncology research and treatment. 40, p. 12-12 1 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Copanlisib in patients with relapsed or refractory follicular lymphoma.

Dreyling, M. H., Santoro, A., Leppa, S., Demeter, J., Follows, G., Lenz, G., Kim, W. S., Mollica, L., Nagler, A., Diong, C. P., Provencio, M., Stevens, D. A., Trevarthen, D., Magagnoli, M., Cupit, L., Yin, S., Hiemeyer, F., -Vargas, J. E. G., Childs, B. H. & Zinzani, P. L., 20 May 2017, In : Journal of Clinical Oncology. 35, 5 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study

Provencio Pulla, M., Santoro, A., Mollica, L., Leppa, S., Follows, G., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., Ozcan, M., Kosinova, M., Bouabdallah, K., Morschhauser, F., Ishida, T., Huang, L., Garcia-Vargas, J., Childs, B. H., Zinzani, P. L. & Dreyling, M., Sep 2017, In : Annals of Oncology. 28, 1 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

EFFICACY AND SAFETY OF COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE CHRONOS-1 STUDY

Zinzani, P. L., Santoro, A., Leppa, S., Demeter, J., Follows, G. A., Lenz, G., Kim, W. S., Mollica, L., Nagler, A., Diong, C. P., Provenciio, M., Stevens, D. A., Trevarthen, D., Maagnoli, M., Cupit, L., Yin, S., Hiemeyer, F., Garcia-Vargas, J., Childs, B. H. & Dreyling, M., 26 Jun 2017, In : Haematologica. 102, p. 314-315 2 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

High Amount of PD-L1+Tumor Associated Macrophages Is Associated with Better Survival in Patients with Primary Testicular Lymphoma

Pollari, M., Bruck, O., Leivonen, S-K., Pellinen, T., Vahamurto, P., Karjalainen-Lindsberg, M-L., Mannisto, S., Kellokumpu-Lehtinen, P-L., Mustjoki, S. & Leppa, S., 7 Dec 2017, In : Blood. 130, Suppl 1, p. Meeting Abstract: 2761 2 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

IMMUNOLOGICAL CHARACTERIZATION OF PH plus ALL BONE MARROW BY MULTIPLEX IMMUNOHISTOCHEMISTRY

Hohtari, H., Bruck, O., Blom, S., Turkki, R., Ribeiro, A., Sinisalo, M., Kovanen, P., Kallioniemi, O., Pellinen, T., Porkka, K. & Mustjoki, S., 26 Jun 2017, In : Haematologica. 102, p. 654-654 1 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) IS REDUCED BY NILOTINIB THERAPY AND PREDICTS MOLECULAR RESPONSE

Sopper, S., Mustjoki, S., Gastl, G., Trajanoski, Z., Giles, F., Hochhaus, A., Janssen, J., Geisler, S., Fuchs, D. & Wolf, D., 26 Jun 2017, In : Haematologica. 102, p. 232-233 2 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Indoleamine 2,3-Dioxygenase (Ido1) activity is increased in early chronic phase Chronic Myelogenous Leukemia (CML) and predicts molecular response to nilotinib therapy

Sopper, S., Mustjoki, S., Geisler, S., Fuchs, D., Hackl, H., Trajanoski, Z., Hochhaus, A. & Wolf, D., Dec 2017, In : European Journal of Immunology. 47, p. 170-170 1 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Low Expression of T/NK-Cell Signature Predicts Poor Survival in Patients with Primary Testicular and Diffuse Large B-Cell Lymphoma

Leivonen, S-K., Pollari, M., Bruck, O., Pellinen, T., Karjalainen-Lindsberg, M-L., Mannisto, S., Kellokumpu-Lehtinen, P-L., Mustjoki, S. & Leppa, S., 7 Dec 2017, In : Blood. 130, 1 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

LOW IL-2 CONCENTRATION FAVORS GENERATION OF EARLY MEMORY T CELLS OVER TERMINAL EEFECTORS DURING CAR T-CELL EXPANSION

Luostarinen, A., Kaartinen, T., Maliniernii, P., Keto, J., Arvas, M., Belt, H., Koponen, J., Loskog, A., Mustjoki, S., Porkka, K., Yla-Herttuala, S. & Korhonen, M., May 2017, In : Cytotherapy. 19, 5, p. S8-S8 1 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

TELOMERE SHORTENING IN CD34+38-BCR-ABL POSITIVE BONE MARROW CELLS FROM NEWLY DIAGNOSED PATIENTS WITH CML CORRELATES WITH THE CLONE SIZE OF THE LEUKEMIC STEM CELL COMPARTMENT

Bouillon, A. -S., Ferreira, M. V., Awad, S. A., Richter, J., Hjorth-Hansen, H., Hummel, S., Schemionek, M., Mustjoki, S., Beier, F. & Bruemmendorf, T. H., 26 Jun 2017, In : Haematologica. 102, p. 231-232 2 p.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Th1/2 Immune Response Signature Predicts Outcome after Dose-Dense Immunochemotherapy in Patients with High Risk Diffuse Large B-Cell Lymphoma - Results from Nordic Lymphoma Group Trials

Autio, M., Leivonen, S-K., Jorgensen, J. M., Karjalainen-Lindsberg, M-L., Beiske, K., Holte, H. & Leppä, S., 7 Dec 2017, In : Blood. 130, 2 p., 4008.

Research output: Contribution to journalMeeting AbstractResearchpeer-review